IL17A and systemic lupus erythematosus: Similarly, IL-17A pathway inhibitors have been recently proposed as a therapeutic option for SLE patients25, since increased circulating levels of IL-17 correlated with disease activity and a Th17/Th1 imbalance have been reported in SLE26, 27, 28.